CC chemokine receptor 6 expression predicts poor prognosis in hepatocellular carcinoma

Liu, Feng; Lv, Hong; Jia, Xinyong; Liu, Guoming; Li, Tao; Xu, Zuowei; Li, Jie

doi:10.1002/jso.23598

Cited by 8 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have reported that the CCL20/CCR6 axis plays a key role in the tumor-chemokine network and promotes tumor progression in HCC and CRC. This axis has been shown to stimulate cell proliferation, probably via regulating the expression of p21, p27, and cyclin-D1 [91,165], induce EMT via PI3K/AKT and Wnt/β-catenin pathways [166], and eventually, promote metastasis [167,168]. The CCL20/CCR6 network facilitates T reg activity and induces immune suppression to mediate cancer cell elimination and metastasis [34].…”

Section: Ccl20mentioning

confidence: 99%

Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers

Thu

Lee

Cho

2020

Cancers

158

131

View full text Add to dashboard Cite

Chemokines are chemotactic cytokines that mediate immune cell chemotaxis and lymphoid tissue development. Recent advances have indicated that chemokines and their cognate receptors play critical roles in cancer-related inflammation and cancer progression. On the basis of these findings, the chemokine system has become a new potential drug target for cancer immunotherapy. In this review, we summarize the essential roles of the complex network of chemokines and their receptors in cancer progression. Furthermore, we discuss the potential value of the chemokine system as a cancer prognostic marker. The chemokine system regulates the infiltration of immune cells into the tumor microenvironment, which induces both pro- and anti-immunity and promotes or suppresses tumor growth and proliferation, angiogenesis, and metastasis. Increasing evidence indicates the promising prognostic value of the chemokine system in cancer patients. While CCL2, CXCL10, and CX3CL1/CX3CR1 can serve as favorable or unfavorable prognostic factors depending on the cancer types, CCL14 and XCL1 possess good prognostic value. Other chemokines such as CXCL1, CXCL8, and CXCL12 are poor prognostic markers. Despite vast advances in our understanding of the complex nature of the chemokine system in tumor biology, knowledge about the multifaceted roles of the chemokine system in different types of cancers is still limited. Further studies are necessary to decipher distinct roles within the chemokine system in terms of cancer progression and to validate their potential value in cancer prognosis.

show abstract

Section: Ccl20mentioning

confidence: 99%

Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers

Thu

Lee

Cho

2020

Cancers

158

131

View full text Add to dashboard Cite

show abstract

“…Immunohistochemical staining was performed as previously described. 32 The scoring was done by two independent observers who were unaware of the clinical data. We separately assembled the nucleus and cytoplasm YAP1 expression according to the established rules.…”

Section: Immunohistochemistrymentioning

confidence: 99%

“…We separately assembled the nucleus and cytoplasm YAP1 expression according to the established rules. 32,33 The cytoplasmic expression of YAP1 was assessed by assigning a proportion score and an intensity score as previously described. The nuclear expression of YAP1 was scored by estimating the proportion of tumor cells with positive nuclear staining (0: none, 1: ≤10%, 2: 10% to ≤50%, and 3: >50%).…”

Section: Immunohistochemistrymentioning

confidence: 99%

Hypoxia induces oncogene yes-associated protein 1 nuclear translocation to promote pancreatic ductal adenocarcinoma invasion via epithelial–mesenchymal transition

Wei

Liu

et al. 2017

Tumour Biol.

Self Cite

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma is one of the most lethal cancers. The Hippo pathway is involved in tumorigenesis and remodeling of tumor microenvironments. Hypoxia exists in the microenvironment of solid tumors, including pancreatic ductal adenocarcinoma and plays a vital role in tumor progression and metastasis. However, it remains unclear how hypoxia interacts with the Hippo pathway to regulate these events. In this study, expressions of yes-associated protein 1 and hypoxia-inducible factor-1α were found to be elevated in pancreatic ductal adenocarcinoma samples compared with those in matched adjacent non-tumor samples. Moreover, hypoxia-inducible factor-1α expression was positively correlated with yes-associated protein 1 level in pancreatic ductal adenocarcinoma tissues. The higher expression of nuclear yes-associated protein 1 was associated with poor histological grade and prognosis for pancreatic ductal adenocarcinoma patients. In vitro, yes-associated protein 1 was highly expressed in pancreatic ductal adenocarcinoma cells. Depletion of yes-associated protein 1 inhibited the invasion of pancreatic ductal adenocarcinoma cells via downregulation of Vimentin, matrix metalloproteinase-2, and matrix metalloproteinase-13, and upregulation of E-cadherin. In addition, hypoxia promoted the invasion of pancreatic ductal adenocarcinoma cells via regulating the targeted genes. Hypoxia also deactivated the Hippo pathway and induced yes-associated protein 1 nuclear translocation. Furthermore, depletion of yes-associated protein 1 or hypoxia-inducible factor-1α suppressed the invasion of pancreatic ductal adenocarcinoma cells under hypoxia. Mechanism studies showed that nuclear yes-associated protein 1 interacted with hypoxia-inducible factor-1α and activated Snail transcription to participate in epithelial-mesenchymal transition-mediated and matrix metalloproteinase-mediated remodeling of tumor microenvironments. Collectively, yes-associated protein 1 is an independent prognostic predictor that interacts with hypoxia-inducible factor-1α to enhance the invasion of pancreatic cancer cells and remodeling of tumor microenvironments. Therefore, yes-associated protein 1 may serve as a novel promising target to enhance therapeutic effects for treating pancreatic cancer.

show abstract

“…Interestingly, together with CCL20, CCR6 expression has been correlated with stage and prognosis in a variety of cancers including hepatocellular carcinoma [14, 15], colorectal carcinoma [16–18], glioma [19], and non-small cell lung cancer [20], and a function for CCR6 in regulation of cancer progression has been putatively demonstrated using cell lines and xenograft models [16, 18, 21, 22]. In breast cancer, higher CCR6 expression levels were linked with tumor stage and grade [23], and incidence of metastasis to the pleura [24].…”

Section: Introductionmentioning

confidence: 99%

The chemokine receptor CCR6 facilitates the onset of mammary neoplasia in the MMTV-PyMT mouse model via recruitment of tumor-promoting macrophages

et al. 2015

View full text Add to dashboard Cite

BackgroundThe expression of the chemokine receptor CCR6 has been previously correlated with higher grades and stages of breast cancer and decreased relapse-free survival. Also, its cognate chemokine ligand CCL20 has been reported to induce proliferation of cultured human breast epithelial cells.MethodsTo establish if CCR6 plays a functional role in mammary tumorigenesis, a bigenic MMTV-PyMT CCR6-null mouse was generated and mammary tumor development was assessed. Levels of tumor-infiltrating immune cells within tumor-bearing mammary glands from MMTV-PyMT Ccr6WT and Ccr6−/− mice were also analyzed.ResultsDeletion of CCR6 delayed tumor onset, significantly reduced the extent of initial hyperplastic outgrowth, and decreased tumor incidence in PyMT transgenic mice. CCR6 was then shown to promote the recruitment of pro-tumorigenic macrophages to the tumor site, facilitating the onset of neoplasia.ConclusionsThis study delineated for the first time a role for CCR6 in the development of breast cancer, and demonstrated a critical function for this receptor in maintaining the pro-tumorigenic cancer microenvironment.Electronic supplementary materialThe online version of this article (doi:10.1186/s12943-015-0394-1) contains supplementary material, which is available to authorized users.

show abstract

CC chemokine receptor 6 expression predicts poor prognosis in hepatocellular carcinoma

Abstract: CCR6 could be used as a molecular marker to predict prognosis for HCC. J. Surg. Oncol. 2014; 110:151-155. © 2014 Wiley Periodicals, Inc.

Cited by 8 publications

References 15 publications

Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers

Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers

Hypoxia induces oncogene yes-associated protein 1 nuclear translocation to promote pancreatic ductal adenocarcinoma invasion via epithelial–mesenchymal transition

The chemokine receptor CCR6 facilitates the onset of mammary neoplasia in the MMTV-PyMT mouse model via recruitment of tumor-promoting macrophages

Contact Info

Product

Resources

About